Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr 17:14:177.
doi: 10.1186/1472-6963-14-177.

Cost-outcome description of clinical pharmacist interventions in a university teaching hospital

Affiliations

Cost-outcome description of clinical pharmacist interventions in a university teaching hospital

James Gallagher et al. BMC Health Serv Res. .

Abstract

Background: Pharmacist interventions are one of the pivotal parts of a clinical pharmacy service within a hospital. This study estimates the cost avoidance generated by pharmacist interventions due to the prevention of adverse drug events (ADE). The types of interventions identified are also analysed.

Methods: Interventions recorded by a team of hospital pharmacists over a one year time period were included in the study. Interventions were assigned a rating score, determined by the probability that an ADE would have occurred in the absence of an intervention. These scores were then used to calculate cost avoidance. Net cost benefit and cost benefit ratio were the primary outcomes. Categories of interventions were also analysed.

Results: A total cost avoidance of €708,221 was generated. Input costs were calculated at €81,942. This resulted in a net cost benefit of €626,279 and a cost benefit ratio of 8.64: 1. The most common type of intervention was the identification of medication omissions, followed by dosage adjustments and requests to review therapies.

Conclusion: This study provides further evidence that pharmacist interventions provide substantial cost avoidance to the healthcare payer. There is a serious issue of patient's regular medication being omitted on transfer to an inpatient setting in Irish hospitals.

PubMed Disclaimer

References

    1. Halvorsen KH, Stensland P, Granas AG. A qualitative study of physicians‘ and nurses’ experiences of multidisciplinary collaboration with pharmacists participating at case conferences. Int J Pharm Pract. 2011;14(5):350–357. doi: 10.1111/j.2042-7174.2011.00129.x. - DOI - PubMed
    1. Kaboli PJ, Hoth AB, McClimon BJ, Schnipper JL. Clinical pharmacists and inpatient medical care: a systematic review. Arch Intern Med. 2006;14(9):955–964. doi: 10.1001/archinte.166.9.955. - DOI - PubMed
    1. Khalili H, Karimzadeh I, Mirzabeigi P, Dashti-Khavidaki S. Evaluation of clinical pharmacist’s interventions in an infectious diseases ward and impact on patient’s direct medication cost. Eur J Intern Med. 2013;14(3):227–233. doi: 10.1016/j.ejim.2012.11.014. - DOI - PubMed
    1. Klopotowska JE, Kuiper R, van Kan HJ, de Pont AC, Dijkgraaf MG, Lie-A-Huen L, Vroom MB, Smorenburg SM. On-ward participation of a hospital pharmacist in a Dutch intensive care unit reduces prescribing errors and related patient harm: an intervention study. Crit Care. 2010;14(5):R174. doi: 10.1186/cc9278. - DOI - PMC - PubMed
    1. Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;14(23):2483–2487. doi: 10.2146/ajhp060674. - DOI - PubMed

Publication types

MeSH terms